Articles tagged "Prophylaxis"

2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
L. J. Myhre¹, K. D. Watt², B. A. Aqel³
¹Pharmacy, Mayo Clinic, Rochester, MN, ²Gastroenterology/Hepatology, Mayo Clinic, Rochester, MN, ³Gastroenterology/Hepatology, Mayo Clinic, Phoenix, AZ
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…
2021 American Transplant Congress
Incidence of Oral Candidiasis in Renal and/or Pancreas Transplant Recipients When Administering Prophylaxis versus No Prophylaxis
L. Von Stein¹, S. Patel¹, L. Wardlow²
¹Transplant, The Ohio State Wexner Medical Center, Columbus, OH, ²Pharmacy, The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Oropharyngeal candidiasis (OC), or thrush, is a fungal infection associated with immunosuppression post renal and or/pancreas transplant. Currently, the role of prophylactic oral nystatin…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
I. Yakubu, Y. Zhang, S. Ijioma, N. V. Carroll, J. Patterson, R. Sterling, G. Gupta
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Practice Patterns in Pneumocystis Jirovecii Pneumonia Prophylaxis in Solid Organ and Bone Marrow Transplant Recipients
S. Cao, K. Khalil, F. Cirrone, S. Mehta
NYU Langone Transplant Institute, New York, NY
*Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred agent for pneumocystis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) and bone marrow transplant (BMT); however, adverse…
2021 American Transplant Congress
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients
K. Fitton, A. Chan, C. Truax, B. Sirandas, T. Larson, L. Smith, A. Carlson
University of Utah Health, Salt Lake City, UT
*Purpose: Invasive fungal infection (IFI) after liver transplant (LT) is associated with significant morbidity and mortality. The optimal antifungal prophylaxis regimen has not been defined.…
2021 American Transplant Congress
Outcomes in High Risk CMV Liver Transplants with Elevated MELD Scores
S. Freedman¹, K. Saunders², T. Sparkes¹, B. Masters¹, M. Plazak¹, K. Saharia³, D. Maluf³, B. Ravichandran²
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD
*Purpose: There is inconclusive evidence on the impact of MELD score on CMV viremia after liver transplantation. Following the implementation of Share 35, liver transplant…
2020 American Transplant Congress
Epidemiology of Invasive Fungal Infections in Heart Transplant Recipients
A. Couture-Cossette¹, A. Puing¹, A. Multani², O. Quintero¹, A. K. Subramanian¹, E. Henricksen³, R. Lee¹, Y. Moayedi⁴, K. Khush⁵, J. J. Teuteberg⁵, D. Y. Ho¹
¹Department of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, ²Department of Infectious Diseases, UCLA, Stanford, CA, ³Pharmacy, Stanford Healthtcare, Stanford, CA, ⁴Department of Cardiology, UHN, Toronto, ON, Canada, ⁵Division of Cardiology, Department of Medicine, Stanford University, Stanford, CA
*Purpose: The incidence and epidemiology of invasive fungal infections (IFI) after heart transplantation (HTx) are influenced by changes in environmental exposures, immunosuppression, and prophylaxis practices.…
2020 American Transplant Congress
Does Antibiotic Prophylaxis at Ureteral Stent Removal Reduce Urinary Tract Infections in Kidney Transplant Recipients?
M. Tarokh¹, B. Frainey², M. Fascelli³, D. Goldfarb¹, A. Wee³, M. Eltemamy³
¹Kidney Transplant Surgery, Cleveland Clinic, Cleveland, OH, ²Glickman Urological and Kidney Institute, Urology, Cleveland Clinic, Cleveland, OH, ³Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Ureteral stents are commonly placed during kidney transplantation (KT). Urinary tract infections (UTI) are a common risk factor after KT and can have detrimental…
2020 American Transplant Congress
Efficacy and Safety According to Dose of Valganciclovir for Cytomegalovirus Prophylaxis in Transplantation Network Meta Analysis
S. Hwang, W. Park, K. Kim, J. Song, S. Lee
Inha University, Incheon, Korea, Republic of
*Purpose: Valgancivlovir is importantly used to prevent post-transplant CMV infection among kidney transplantation patients. However, the dose of such drug being used still remains controversial…